{"category":{"kind":"industry","slug":"therapeutics","name":"Therapeutics","tagline":null,"description":null,"synonyms":[],"target_queries":[],"added_via":"pr","added_at":"2026-09-03T06:08:10.283Z","updated_at":"2026-09-03T06:08:10.283Z","example":false,"profile_url":"/industries/therapeutics","is_stub":true,"member_count":72,"member_counts":{"accelerator":1,"company":71}},"members":[{"listing_type":"company","name":"Sling Therapeutics","slug":"sling-therapeutics","tagline":"Developing oral therapies for thyroid eye disease","description":"Sling Therapeutics is a biopharmaceutical company developing treatments for thyroid eye disease. Its lead pipeline program, linsitinib, is in late-stage development as an oral therapy for TED. The company is based in Ann Arbor, Michigan.","url":"https://slingtx.com/","is_stealth":false,"normalized_domain":"slingtx.com","normalized_url_key":"slingtx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://slingtx.com/wp-content/uploads/2021/11/cropped-favicon2_1-32x32.png","links":[],"entry_points":[{"kind":"homepage","url":"https://slingtx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://slingtx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"2b0cf862-877d-467f-bded-5f45fde90b03"},"categories":["Biotech","Healthcare","Therapeutics"],"stage":null,"founded_year":null,"location":"Ann Arbor, Michigan","pricing":null,"twitter":null,"github":null,"linkedin":"https://www.linkedin.com/company/sling-tx","contact_email":null,"added_at":"2026-09-18T02:16:28.550Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-18T02:16:28.550Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-18T02:16:28.550Z","updated_at":"2026-09-18T02:16:28.550Z"}},{"listing_type":"company","name":"RonanRx Inc.","slug":"ronanrx-inc","tagline":"Full Stack Pharmaceutical Company for Personalized Peptides and GLP-1s","description":"RonanRX is a full-stack pharmaceutical company, starting with personalized peptides and GLP-1s.\n\nIn our first 10 weeks, we went from having no pharmacy to being licensed in 33 states. Since launch, we’ve grown 50% week over week.\n\nWe manufacture the medications ourselves, sell directly to patients, and eliminate the layers of middlemen that make prescription drugs more expensive.\n\nWhat makes this possible is AI.\n\nTraditional pharmaceutical companies are built to manufacture one drug for millions of people. RonanRX is purpose-built to personalize treatment for each patient: different biology, different response, different dose.\n\nPatients come directly to RonanRX or through doctors using our platform. Every patient completes our medical intake, meets with a licensed doctor through our telehealth platform, and receives a personalized prescription when appropriate. From there, we manufacture the medication ourselves and deliver it directly to the patient.\n\nLabs, wearables, medical history, treatment response, and other health data feed back into the platform so doctors can continuously refine treatment over time.\n\nBefore AI, doing this for every patient at scale was impossible.\n\nWe didn't invent the demand we are seeing. 80 Million people are on a GLP-1 and millions more are using Peptides. We're building a better way to manufacture, personalize, prescribe, and deliver them.\n\nOur founders have built and exited multiple companies, raised more than $100M, built a $50M U.S. medical manufacturing business, and spent years developing peptide therapeutics at companies including Eli Lilly and AbbVie.\n\nWe’re just getting started with peptides and GLP-1s. Next comes hormone therapy and the rest of personalized medicine.\n\nRonanRx Inc. is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://ronanrx.com/","is_stealth":false,"normalized_domain":"ronanrx.com","normalized_url_key":"ronanrx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ce1dcec626f9c7fdc1ea66f4d7850c7a32015773.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/ronanrx-inc","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://ronanrx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://ronanrx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Health Tech","Telehealth","Therapeutics"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:33:21.713Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","Health Tech","Telehealth","Therapeutics"],"one_liner_for_search":"RonanRx Inc. — Full Stack Pharmaceutical Company for Personalized Peptides and GLP-1s (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare","Former names: Ronan Rx Inc.","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:33:21.713Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"health-tech","name":"Health Tech","note":null,"profile_url":"/industries/health-tech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"telehealth","name":"Telehealth","note":null,"profile_url":"/industries/telehealth"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:33:21.713Z","updated_at":"2026-09-03T08:33:21.713Z"}},{"listing_type":"company","name":"WonderTx","slug":"wondertx","tagline":"Extrapolative AI to unlock First-in-Class drugs","description":"We’re an AI-native biotech, working on replacing needles with pills. Many drugs, like insulin or Ozempic, are wonderful except you have to inject them. We discover new molecules that you can take as a pill instead. Because the pills operate on biology which has been shown to be effective in people, rather than merely in animal models of disease, we avoid what has historically been the single biggest risk in drug discovery.  This should dramatically increase our probability of success.\n\nThere’s $200B of treatable diseases and validated human biology without a pill because discovery programs lack a tractable chemical starting point. This is a zero-shot inference problem, because these targets have no training data, so LLMs and other historical interpolative AI approaches are insufficient. Instead, we are building our own extrapolative frontier models that reason beyond their training data. Most critically, we have repeatedly validated our platform on both our own and partner programs. On 4 biologically- and structurally-diverse targets where we had zero training data, we successfully picked binders that were validated experimentally, with confirmation ranging from primary screen hits to crystallographic structures.\n\nWonderTx is a Y Combinator company (Summer 2026). YC-listed status: Active.","url":"https://wondertx.ai/","is_stealth":false,"normalized_domain":"wondertx.ai","normalized_url_key":"wondertx.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/08d90d66366f5066cf3ad5ae02f156dc4bcc8ebe.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/wondertx","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://wondertx.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://wondertx.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","AI-powered Drug Discovery","Generative AI","Biotech"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; Remote","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:26:18.861Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2026","AI-powered Drug Discovery","Generative AI","Biotech"],"one_liner_for_search":"WonderTx — Extrapolative AI to unlock First-in-Class drugs (Y Combinator Summer 2026)","canonical_facts":["Y Combinator batch: Summer 2026","YC company status: Active","Team size (per YC directory): 3","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: A Company in Stealth Mode Incorporated","Regions (per YC): United States of America, America / Canada, Remote, Fully Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:26:18.861Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"generative-ai","name":"Generative AI","note":null,"profile_url":"/industries/generative-ai"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:26:18.861Z","updated_at":"2026-09-03T08:26:18.861Z"}},{"listing_type":"company","name":"FinalDose","slug":"finaldose","tagline":"Programmable DNA drug destroying all cancers, unlocking 80% of targets","description":"FinalDose is building the first programmable drug - a single smart drug molecule that you can insert any diseased genetic code and it can search and destroy cells upon DNA recognition.  Unlocking 80% of undruggable targets today. Starting with all cancers.\n\nFinalDose is a Y Combinator company (Spring 2026). YC-listed status: Active.","url":"https://www.finaldose.ai/","is_stealth":false,"normalized_domain":"finaldose.ai","normalized_url_key":"finaldose.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/5910d81ebbfb17b7489c9613332140c02f40b7f4.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/finaldose","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.finaldose.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.finaldose.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Artificial Intelligence","Gene Therapy","Genetic Engineering"],"stage":null,"founded_year":null,"location":"London, England, United Kingdom","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:15:27.382Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Spring 2026","Artificial Intelligence","Gene Therapy","Therapeutics","Genetic Engineering"],"one_liner_for_search":"FinalDose — Programmable DNA drug destroying all cancers, unlocking 80% of targets (Y Combinator Spring 2026)","canonical_facts":["Y Combinator batch: Spring 2026","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United Kingdom, Europe"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:15:27.382Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"genetic-engineering","name":"Genetic Engineering","note":null,"profile_url":"/industries/genetic-engineering"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:15:27.382Z","updated_at":"2026-09-03T08:15:27.382Z"}},{"listing_type":"company","name":"Blank Bio","slug":"blank-bio","tagline":"RNA intelligence for precision medicine","description":"Blank Bio is an applied AI research lab focused on increasing the success rates of clinical trials. We do this by training RNA foundation models that learn the patterns that shape disease progression and patient response to treatment. We aim to help pharma make more informed decisions in clinical trials by capturing the biology that makes each patient’s tumour unique. \n\nWe’re a technical team of AI scientists and engineers from companies including Recursion, Deep Genomics, DeepMind, and Amazon, and institutions including Memorial Sloan Kettering Cancer Centre, Stanford, and the Vector Institute.\n\nBlank Bio is a Y Combinator company (Summer 2025). YC-listed status: Active.","url":"https://www.blank.bio/","is_stealth":false,"normalized_domain":"blank.bio","normalized_url_key":"blank.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/7849a6bd6406353cb8f9f09c914d22bd1f4c0650.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/blank-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.blank.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.blank.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T08:08:18.560Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2025"],"one_liner_for_search":"Blank Bio — RNA intelligence for precision medicine (Y Combinator Summer 2025)","canonical_facts":["Y Combinator batch: Summer 2025","YC company status: Active","Team size (per YC directory): 6","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Orthrus Bio","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T08:08:18.560Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T08:08:18.560Z","updated_at":"2026-09-03T08:08:18.560Z"}},{"listing_type":"company","name":"Exin Therapeutics","slug":"exin-therapeutics","tagline":"AI drug discovery platform for neurotherapeutics","description":"We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house.\n\nWe are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL.\n\nIn 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding.\n\nExin Therapeutics is a Y Combinator company (Winter 2025). YC-listed status: Active.","url":"https://www.exintherapeutics.com/","is_stealth":false,"normalized_domain":"exintherapeutics.com","normalized_url_key":"exintherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/61d9c34b51f9b98cbfdb92bc0014e3569c29b36c.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/exin-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.exintherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.exintherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Neurotechnology","Biotech"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:54:21.458Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2025","Neurotechnology","Biotech","Therapeutics"],"one_liner_for_search":"Exin Therapeutics — AI drug discovery platform for neurotherapeutics (Y Combinator Winter 2025)","canonical_facts":["Y Combinator batch: Winter 2025","YC company status: Active","Team size (per YC directory): 9","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: EI Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:54:21.458Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"neurotechnology","name":"Neurotechnology","note":null,"profile_url":"/industries/neurotechnology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:54:21.458Z","updated_at":"2026-09-03T07:54:21.458Z"}},{"listing_type":"company","name":"Uncommon Therapeutics","slug":"uncommon-therapeutics","tagline":"A Disease Focused Biotech, Building Multiple Billion Dollar Drugs","description":"Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.\n\nUncommon Therapeutics is a Y Combinator company (Winter 2025). YC-listed status: Active.","url":"https://www.uncommontherapeutics.com/","is_stealth":false,"normalized_domain":"uncommontherapeutics.com","normalized_url_key":"uncommontherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/791a2a1e71f62bafa47311d3711d9cab4712eea4.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/uncommon-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.uncommontherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.uncommontherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Gene Therapy","CRISPR","Biotechnology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:54:06.858Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2025","Gene Therapy","CRISPR","Biotechnology"],"one_liner_for_search":"Uncommon Therapeutics — A Disease Focused Biotech, Building Multiple Billion Dollar Drugs (Y Combinator Winter 2025)","canonical_facts":["Y Combinator batch: Winter 2025","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:54:06.858Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"crispr","name":"CRISPR","note":null,"profile_url":"/industries/crispr"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:54:06.858Z","updated_at":"2026-09-03T07:54:06.858Z"}},{"listing_type":"company","name":"Kopra Bio","slug":"kopra-bio","tagline":"Genetically engineered viruses that teach your immune system to kill…","description":"Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.\n\nKopra Bio is a Y Combinator company (Summer 2024). YC-listed status: Active.","url":"https://www.kopra.bio/","is_stealth":false,"normalized_domain":"kopra.bio","normalized_url_key":"kopra.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/acdb0c2a3124d9e5717a63d0231af9b6f7447919.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/kopra-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.kopra.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.kopra.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Gene Therapy","Synthetic Biology","Biotech","Oncology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:49:28.291Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2024","Gene Therapy","Synthetic Biology","Biotech","Therapeutics","Oncology"],"one_liner_for_search":"Kopra Bio — Genetically engineered viruses that teach your immune system to kill… (Y Combinator Summer 2024)","canonical_facts":["Y Combinator batch: Summer 2024","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: GlioTx","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:49:28.291Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:49:28.291Z","updated_at":"2026-09-03T07:49:28.291Z"}},{"listing_type":"company","name":"ParcelBio","slug":"parcelbio","tagline":"Elevated mRNA for transformative medicines.","description":"ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.\n\nParcelBio is a Y Combinator company (Winter 2024). YC-listed status: Active.","url":"https://parcelbio.com/","is_stealth":false,"normalized_domain":"parcelbio.com","normalized_url_key":"parcelbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/74f762bd0f8856c1dbe4d716afa6585e44f03870.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/parcelbio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://parcelbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://parcelbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Gene Therapy","Synthetic Biology","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:46:05.163Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2024","Gene Therapy","Synthetic Biology","Biotech","Therapeutics","Drug discovery"],"one_liner_for_search":"ParcelBio — Elevated mRNA for transformative medicines. (Y Combinator Winter 2024)","canonical_facts":["Y Combinator batch: Winter 2024","YC company status: Active","Team size (per YC directory): 6","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Parcel Therapuetics, Parcel Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:46:05.163Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:46:05.163Z","updated_at":"2026-09-03T07:46:05.163Z"}},{"listing_type":"company","name":"Granza Bio","slug":"granza-bio","tagline":"Building programmable therapeutics for the immune system","description":"Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.\n\nGranza Bio is a Y Combinator company (Winter 2024). YC-listed status: Active.","url":"https://www.granzabio.com/","is_stealth":false,"normalized_domain":"granzabio.com","normalized_url_key":"granzabio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/e4fe5f43800f16c0ca16303f58b955037e3f2bc1.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/granza-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.granzabio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.granzabio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Synthetic Biology","Biotech","Oncology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:45:07.063Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2024","Synthetic Biology","Biotech","Healthcare","Therapeutics","Oncology"],"one_liner_for_search":"Granza Bio — Building programmable therapeutics for the immune system (Y Combinator Winter 2024)","canonical_facts":["Y Combinator batch: Winter 2024","YC company status: Active","Team size (per YC directory): 8","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Zyme Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:45:07.063Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:45:07.063Z","updated_at":"2026-09-03T07:45:07.063Z"}},{"listing_type":"company","name":"Junction Bioscience","slug":"junction-bioscience","tagline":"AI Hypothesis Engine for Molecular Discovery","description":"Junction Bioscience is building an autonomous AI scientist to navigate the discovery of transformative medicines. Our scientific hypothesis engine iterates upon breakthrough chemistry from the laboratory to achieve clarity and control over the molecular basis of disease. We focus on the intersection of neuroinflammation and immunology where uncommon molecular insights position us to develop best-in-class therapies for millions of patients in need.\n\nJunction Bioscience is a Y Combinator company (Winter 2024). YC-listed status: Active.","url":"https://www.junction.bio/","is_stealth":false,"normalized_domain":"junction.bio","normalized_url_key":"junction.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/3c382f7f1170e4d96b382d69430f2fc2c9fffe94.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/junction-bioscience","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.junction.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.junction.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics"],"stage":null,"founded_year":null,"location":"New York City, NY, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:45:03.587Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2024"],"one_liner_for_search":"Junction Bioscience — AI Hypothesis Engine for Molecular Discovery (Y Combinator Winter 2024)","canonical_facts":["Y Combinator batch: Winter 2024","YC company status: Active","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:45:03.587Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:45:03.587Z","updated_at":"2026-09-03T07:45:03.587Z"}},{"listing_type":"company","name":"Evolvere BioSciences","slug":"evolvere-biosciences","tagline":"Making Next-Generation Antibiotics that Outpace Bacterial Evolution","description":"🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. \n\n☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. \n\n🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️.\n\nWe are a team of biochemists and evolutionary biologists who met at the University of Oxford.\n\nEvolvere BioSciences is a Y Combinator company (Summer 2024). YC-listed status: Active.","url":"https://evolverebiosciences.com/","is_stealth":false,"normalized_domain":"evolverebiosciences.com","normalized_url_key":"evolverebiosciences.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/dd3489b7e5a5f2d3f7cc49de65917a83134da0a3.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/evolvere-biosciences","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://evolverebiosciences.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://evolverebiosciences.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","AI-powered Drug Discovery","Artificial Intelligence","Biotech","Biotechnology"],"stage":null,"founded_year":null,"location":"Oxford, England, United Kingdom","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:44:24.123Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2024","AI-powered Drug Discovery","Artificial Intelligence","Biotech","Therapeutics","Biotechnology"],"one_liner_for_search":"Evolvere BioSciences — Making Next-Generation Antibiotics that Outpace Bacterial Evolution (Y Combinator Summer 2024)","canonical_facts":["Y Combinator batch: Summer 2024","YC company status: Active","Team size (per YC directory): 3","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United Kingdom, Europe"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:44:24.123Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:44:24.123Z","updated_at":"2026-09-03T07:44:24.123Z"}},{"listing_type":"company","name":"Eris Biotech","slug":"eris-biotech","tagline":"Our drugs engage the immune system to fight tumors","description":"We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.\n\nEris Biotech is a Y Combinator company (Winter 2024). YC-listed status: Active.","url":"https://www.erisbio.com/","is_stealth":false,"normalized_domain":"erisbio.com","normalized_url_key":"erisbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/b16bbab6bd8003573ebc3410a08531b90c3427fd.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/eris-biotech","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.erisbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.erisbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery","Oncology"],"stage":null,"founded_year":null,"location":"Lehi, UT, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:44:18.257Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2024","Biotech","Therapeutics","Drug discovery","Oncology"],"one_liner_for_search":"Eris Biotech — Our drugs engage the immune system to fight tumors (Y Combinator Winter 2024)","canonical_facts":["Y Combinator batch: Winter 2024","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:44:18.257Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:44:18.257Z","updated_at":"2026-09-03T07:44:18.257Z"}},{"listing_type":"company","name":"Velorum Therapeutics","slug":"velorum-therapeutics","tagline":"Breakthrough medicines unlocking the biology of heme","description":"Velorum Therapeutics is developing breakthrough medicines by unlocking the biology of heme.\n\nVelorum Therapeutics is a Y Combinator company (Winter 2024). YC-listed status: Active.","url":"https://www.velorumtx.com/","is_stealth":false,"normalized_domain":"velorumtx.com","normalized_url_key":"velorumtx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/f201fcf7f4408f2acdedabe7f9bef2baabec8369.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/velorum-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.velorumtx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.velorumtx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery","Oncology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:43:18.066Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2024","Biotech","Healthcare","Therapeutics","Drug discovery","Oncology"],"one_liner_for_search":"Velorum Therapeutics — Breakthrough medicines unlocking the biology of heme (Y Combinator Winter 2024)","canonical_facts":["Y Combinator batch: Winter 2024","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:43:18.066Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:43:18.066Z","updated_at":"2026-09-03T07:43:18.066Z"}},{"listing_type":"company","name":"SynsoryBio","slug":"synsorybio","tagline":"\"If-then\" conditional logic for protein drugs","description":"SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.\n\nSynsoryBio is a Y Combinator company (Winter 2024). YC-listed status: Active.","url":"https://www.synsorybio.com/","is_stealth":false,"normalized_domain":"synsorybio.com","normalized_url_key":"synsorybio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/e2b7538a15335c79e864ff7431e761c3feca0797.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/synsorybio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.synsorybio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.synsorybio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Synthetic Biology","Biotech","Oncology"],"stage":null,"founded_year":null,"location":"Boston, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:39:17.707Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2024","Synthetic Biology","Biotech","Therapeutics","Oncology"],"one_liner_for_search":"SynsoryBio — \"If-then\" conditional logic for protein drugs (Y Combinator Winter 2024)","canonical_facts":["Y Combinator batch: Winter 2024","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:39:17.707Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:39:17.707Z","updated_at":"2026-09-03T07:39:17.707Z"}},{"listing_type":"company","name":"Nanograb","slug":"nanograb","tagline":"Deliver genes to any cell with AI","description":"Nanograb is a computational drug discovery company that uses AI to create novel targeted non-viral gene therapy vectors. Our platform designs unique combinations of small peptide binders attached to nanoparticles to safely deliver genetic medicines to specific cells and tissues in the body at scale.\n\nNanograb is a Y Combinator company (Summer 2023). YC-listed status: Active.","url":"https://nanograb.com/","is_stealth":false,"normalized_domain":"nanograb.com","normalized_url_key":"nanograb.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/9ae1f1866a70286591b56aa5fd2f81bdf18af255.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/nanograb","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://nanograb.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://nanograb.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","AI-powered Drug Discovery","Nanomedicine","Biotech","Drug Delivery","Therapeutics"],"stage":null,"founded_year":null,"location":"London, England, United Kingdom","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:35:07.337Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2023","AI-powered Drug Discovery","Nanomedicine","Biotech","Drug Delivery","Therapeutics"],"one_liner_for_search":"Nanograb — Deliver genes to any cell with AI (Y Combinator Summer 2023)","canonical_facts":["Y Combinator batch: Summer 2023","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Regions (per YC): United Kingdom, Europe"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:35:07.337Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-delivery","name":"Drug Delivery","note":null,"profile_url":"/industries/drug-delivery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"nanomedicine","name":"Nanomedicine","note":null,"profile_url":"/industries/nanomedicine"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:35:07.337Z","updated_at":"2026-09-03T07:35:07.337Z"}},{"listing_type":"company","name":"Modulari-T","slug":"modulari-t","tagline":"We teach your immune system to attack and cure cancer","description":"Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise.\n\nModulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue.\n\nModulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.\n\nModulari-T is a Y Combinator company (Winter 2023). YC-listed status: Active.","url":"https://modularit.bio/","is_stealth":false,"normalized_domain":"modularit.bio","normalized_url_key":"modularit.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/cdfde836f1d168c7ec0299ab6b4daf90d112f929.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/modulari-t","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://modularit.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://modularit.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Gene Therapy","Cell Therapy","Synthetic Biology","Biotech","Oncology"],"stage":null,"founded_year":null,"location":"Montreal, QC, Canada; San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:28:22.865Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2023","Gene Therapy","Cell Therapy","Synthetic Biology","Biotech","Oncology"],"one_liner_for_search":"Modulari-T — We teach your immune system to attack and cure cancer (Y Combinator Winter 2023)","canonical_facts":["Y Combinator batch: Winter 2023","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Modulari-T Biosciences","Regions (per YC): Canada, United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:28:22.865Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:28:22.865Z","updated_at":"2026-09-03T07:28:22.865Z"}},{"listing_type":"company","name":"Adventris Pharmaceuticals","slug":"adventris-pharmaceuticals","tagline":"Adventris makes cancer vaccines","description":"Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first \"off-the-shelf\" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths.\n\nIf you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com\n\nAdventris Pharmaceuticals is a Y Combinator company (Winter 2023). YC-listed status: Active.","url":"https://www.adventris.com/","is_stealth":false,"normalized_domain":"adventris.com","normalized_url_key":"adventris.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/5c8bb0a987c29df94410bb9cc6ab7db9eb0d6478.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/adventris-pharmaceuticals","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.adventris.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.adventris.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Biotech","Therapeutics","Drug discovery","Oncology"],"stage":null,"founded_year":null,"location":"Baltimore, MD, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:28:14.694Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2023","Biotech","Healthcare","Therapeutics","Drug discovery","Oncology"],"one_liner_for_search":"Adventris Pharmaceuticals — Adventris makes cancer vaccines (Y Combinator Winter 2023)","canonical_facts":["Y Combinator batch: Winter 2023","YC company status: Active","Team size (per YC directory): 7","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Elimivax","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:28:14.694Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:28:14.694Z","updated_at":"2026-09-03T07:28:14.694Z"}},{"listing_type":"company","name":"Persist AI","slug":"persist-ai","tagline":"Developing long-lasting drug formulations 50% faster","description":"It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.\n\nPersist AI is a Y Combinator company (Winter 2023). YC-listed status: Active.","url":"https://www.persist.ai/","is_stealth":false,"normalized_domain":"persist.ai","normalized_url_key":"persist.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/eeb1e38a6ca6e6061c101deae73f22c28c142596.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/persist-ai","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.persist.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.persist.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Machine Learning","Robotics","Microfluidics","Nanotechnology","Therapeutics"],"stage":null,"founded_year":null,"location":"Sacramento, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:28:03.785Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2023","Machine Learning","Robotics","Microfluidics","Nanotechnology","Therapeutics"],"one_liner_for_search":"Persist AI — Developing long-lasting drug formulations 50% faster (Y Combinator Winter 2023)","canonical_facts":["Y Combinator batch: Winter 2023","YC company status: Active","Team size (per YC directory): 6","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Persist AI, Persist AI Formulations Corp","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:28:03.785Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"machine-learning","name":"Machine Learning","note":null,"profile_url":"/industries/machine-learning"},{"kind":"industry","slug":"microfluidics","name":"Microfluidics","note":null,"profile_url":"/industries/microfluidics"},{"kind":"industry","slug":"nanotechnology","name":"Nanotechnology","note":null,"profile_url":"/industries/nanotechnology"},{"kind":"industry","slug":"robotics","name":"Robotics","note":null,"profile_url":"/industries/robotics"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:28:03.785Z","updated_at":"2026-09-03T07:28:03.785Z"}},{"listing_type":"company","name":"Relevium Medical","slug":"relevium-medical","tagline":"Platform injectable gel based therapeutic for osteoarthritis","description":"Relevium Medical is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease.\nRight now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. \nTo date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. \nInsurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity.\nThis platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.\n\nRelevium Medical is a Y Combinator company (Summer 2022). YC-listed status: Active.","url":"https://relevium-medical.com/","is_stealth":false,"normalized_domain":"relevium-medical.com","normalized_url_key":"relevium-medical.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/fe3f53ef710ec5758d984168f33594337d5df8ae.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/relevium-medical","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://relevium-medical.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://relevium-medical.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Medical Devices","Drug discovery"],"stage":null,"founded_year":null,"location":"Galway, County Galway, Ireland","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:19:15.666Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2022","Medical Devices","Healthcare","Therapeutics","Drug discovery"],"one_liner_for_search":"Relevium Medical — Platform injectable gel based therapeutic for osteoarthritis (Y Combinator Summer 2022)","canonical_facts":["Y Combinator batch: Summer 2022","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Relevium, ReleviumBio","Regions (per YC): Ireland, Europe"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:19:15.666Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"medical-devices","name":"Medical Devices","note":null,"profile_url":"/industries/medical-devices"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:19:15.666Z","updated_at":"2026-09-03T07:19:15.666Z"}},{"listing_type":"company","name":"Serinus Biosciences","slug":"serinus-biosciences","tagline":"Combinations therapy by rational design","description":"Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.\n\nSerinus Biosciences is a Y Combinator company (Summer 2022). YC-listed status: Active.","url":"https://www.serinus.bio/","is_stealth":false,"normalized_domain":"serinus.bio","normalized_url_key":"serinus.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/b6e7bac94ec8bfc7378ed11602bae7ea50215536.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/serinus-biosciences","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.serinus.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.serinus.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Oncology"],"stage":null,"founded_year":null,"location":"New York City, NY, USA; New York, NY, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:14:13.371Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2022","Biotech","Therapeutics","Oncology"],"one_liner_for_search":"Serinus Biosciences — Combinations therapy by rational design (Y Combinator Summer 2022)","canonical_facts":["Y Combinator batch: Summer 2022","YC company status: Active","Team size (per YC directory): 6","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Serinus","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:14:13.371Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:14:13.371Z","updated_at":"2026-09-03T07:14:13.371Z"}},{"listing_type":"company","name":"Cisterna Biologics","slug":"cisterna-biologics","tagline":"High quality mRNA for therapeutic application","description":"Founded in 2022 and based in San Diego, California, Cisterna Biologics is a technology company. It aims to solve some of the challenges currently facing the biotech industry to develop mRNA-based therapeutics – quality, quantity, longevity and cost of mRNA. As mRNA technology matures, it becomes imperative that these issues are solved so we can fully explore mRNA's endless possibilities as a therapeutic.\n\nCisterna uses proprietary technologies to either remove a contaminant at its source or replace the source itself. For example, to remove double-stranded RNA (dsRNA), we use ribozymes - molecular scissors - to precisely cut the mRNA at its 3’ end. This assures not only 3’ homogeneity, but also eliminates dsRNA, which are primarily produced due to self-templated additions at the 3’ end. Utilizing a PCR-like system to amplify the DNA template in large quantities eliminates the requirement for plasmid enrichment in bacteria, the prime source of endotoxin contamination. These are just a few examples of Cisterna’s powerful technologies being used to achieve our goal of 10x higher quality mRNA for therapeutic application.\n\nCisterna Biologics is a Y Combinator company (Summer 2022). YC-listed status: Active.","url":"https://www.cisternabx.com/","is_stealth":false,"normalized_domain":"cisternabx.com","normalized_url_key":"cisternabx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/fa3a5ab85434b41a7ce57fae09e3c4645bc55f02.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/cisterna-biologics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.cisternabx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.cisternabx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Synthetic Biology","Biotech","Therapeutics"],"stage":null,"founded_year":null,"location":"San Diego, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:11:28.397Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2022","Synthetic Biology","Biotech","Therapeutics"],"one_liner_for_search":"Cisterna Biologics — High quality mRNA for therapeutic application (Y Combinator Summer 2022)","canonical_facts":["Y Combinator batch: Summer 2022","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare","Former names: Cisterna Biologics LLC, Cisterna Biologic","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:11:28.397Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:11:28.397Z","updated_at":"2026-09-03T07:11:28.397Z"}},{"listing_type":"company","name":"Eugit Therapeutics","slug":"eugit-therapeutics","tagline":"Enabling Tissue Targeting of Therapies","description":"Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.\n\nCofounded by George Church (Harvard) and funded by Y Combinator (S22).\n\nEugit Therapeutics is a Y Combinator company (Summer 2022). YC-listed status: Active.","url":"https://www.eugittx.com/","is_stealth":false,"normalized_domain":"eugittx.com","normalized_url_key":"eugittx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/a88b74cc086730f852f068c605f2dcaa54b40a16.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/eugit-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.eugittx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.eugittx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Cell Therapy","Synthetic Biology","Oncology","Biotechnology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; South San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:11:22.895Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2022","Cell Therapy","Synthetic Biology","Therapeutics","Oncology","Biotechnology"],"one_liner_for_search":"Eugit Therapeutics — Enabling Tissue Targeting of Therapies (Y Combinator Summer 2022)","canonical_facts":["Y Combinator batch: Summer 2022","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: EUGIT Tx, EUGIT Therapeutics, Eugit, Eugit Therapeutics Inc","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:11:22.895Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"cell-therapy","name":"Cell Therapy","note":null,"profile_url":"/industries/cell-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:11:22.895Z","updated_at":"2026-09-03T07:11:22.895Z"}},{"listing_type":"company","name":"Origami Therapeutics, Inc.","slug":"origami-therapeutics-inc","tagline":"Oral drugs to halt neurodegeneration","description":"Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified small molecules that reduce the toxic mutated protein, suppress mutant protein-induced toxicities in human disease neurons and get into the brain. We anticipate that this approach will be broadly applicable to traditionally “undruggable” targets in other neurological diseases.\n\nOrigami Therapeutics, Inc. is a Y Combinator company (Winter 2022). YC-listed status: Active.","url":"https://origamitherapeutics.com/","is_stealth":false,"normalized_domain":"origamitherapeutics.com","normalized_url_key":"origamitherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ec01151ea9fbf839d64b9d2a17dedc03fb322eeb.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/origami-therapeutics-inc","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://origamitherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://origamitherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"San Diego, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:10:33.522Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2022","Biotech","Therapeutics","Drug discovery"],"one_liner_for_search":"Origami Therapeutics, Inc. — Oral drugs to halt neurodegeneration (Y Combinator Winter 2022)","canonical_facts":["Y Combinator batch: Winter 2022","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:10:33.522Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:10:33.522Z","updated_at":"2026-09-03T07:10:33.522Z"}},{"listing_type":"company","name":"Andson Biotech","slug":"andson-biotech","tagline":"Empowering Mass Spec for Biotech and Beyond","description":"Andson Biotech helps pharmaceutical companies measure difficult to detect chemicals that they need to measure while developing and manufacturing drugs like cell-therapies or biologics. Drug companies want to use our technologies to get fast and accurate chemical measurements they do thousands of times per day for drug development and quality control.\n\nAndson Biotech is a Y Combinator company (Winter 2022). YC-listed status: Active.","url":"http://www.andsonbiotech.com/","is_stealth":false,"normalized_domain":"andsonbiotech.com","normalized_url_key":"andsonbiotech.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/8495f5832705b897265e143f4ea26b9403783542.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/andson-biotech","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"http://www.andsonbiotech.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"http://www.andsonbiotech.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Gene Therapy","Hard Tech","Biotech","Therapeutics"],"stage":null,"founded_year":null,"location":"Atlanta, GA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:07:30.325Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2022","Gene Therapy","Hard Tech","Biotech","Healthcare","Therapeutics"],"one_liner_for_search":"Andson Biotech — Empowering Mass Spec for Biotech and Beyond (Y Combinator Winter 2022)","canonical_facts":["Y Combinator batch: Winter 2022","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:07:30.325Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"hard-tech","name":"Hard Tech","note":null,"profile_url":"/industries/hard-tech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:07:30.325Z","updated_at":"2026-09-03T07:07:30.325Z"}},{"listing_type":"company","name":"Alixia","slug":"alixia","tagline":"Targeting the Tumor Ecosystem to address cancer drug resistance.","description":"Our compounds disrupt the metabolic and\ninflammatory triggers in both cancer and quasi-cancerous\ncells in the tumor microenvironment. By impacting multiple cell\ntypes, we are enabling effective, lasting cancer treatments.\n\nAlixia is a Y Combinator company (Winter 2022). YC-listed status: Active.","url":"https://www.alixia.com/","is_stealth":false,"normalized_domain":"alixia.com","normalized_url_key":"alixia.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ff4093c59629c7638e73b36eb069911e0922c140.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/alixia","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.alixia.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.alixia.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery","Oncology","Biotechnology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:03:09.927Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2022","Biotech","Therapeutics","Drug discovery","Oncology","Biotechnology"],"one_liner_for_search":"Alixia — Targeting the Tumor Ecosystem to address cancer drug resistance. (Y Combinator Winter 2022)","canonical_facts":["Y Combinator batch: Winter 2022","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Guided Clarity","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:03:09.927Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"oncology","name":"Oncology","note":null,"profile_url":"/industries/oncology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:03:09.927Z","updated_at":"2026-09-03T07:03:09.927Z"}},{"listing_type":"company","name":"Keylika","slug":"keylika","tagline":"Redefining the Standard of Care for Iron Deficiency Anemia","description":"Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. \n\nOur first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.\n\nKeylika is a Y Combinator company (Summer 2022). YC-listed status: Active.","url":"https://www.keylika.com/","is_stealth":false,"normalized_domain":"keylika.com","normalized_url_key":"keylika.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/bd12fc4dc5d053441f31a9c528579e0d16f3449e.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/keylika","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.keylika.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.keylika.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","AI-powered Drug Discovery","Medical Devices","Drug Delivery","Nanotechnology"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; Walnut Creek, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T07:00:15.920Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2022","AI-powered Drug Discovery","Medical Devices","Drug Delivery","Nanotechnology","Therapeutics"],"one_liner_for_search":"Keylika — Redefining the Standard of Care for Iron Deficiency Anemia (Y Combinator Summer 2022)","canonical_facts":["Y Combinator batch: Summer 2022","YC company status: Active","Team size (per YC directory): 1","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T07:00:15.920Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"drug-delivery","name":"Drug Delivery","note":null,"profile_url":"/industries/drug-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"medical-devices","name":"Medical Devices","note":null,"profile_url":"/industries/medical-devices"},{"kind":"industry","slug":"nanotechnology","name":"Nanotechnology","note":null,"profile_url":"/industries/nanotechnology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T07:00:15.920Z","updated_at":"2026-09-03T07:00:15.920Z"}},{"listing_type":"company","name":"SFA Therapeutics","slug":"sfa-therapeutics-inc","tagline":"Regulating the immune system to block cancer & autoimmune diseases","description":"SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.\n\nSFA Therapeutics is a Y Combinator company (Summer 2021). YC-listed status: Active.","url":"https://sfatherapeutics.com/","is_stealth":false,"normalized_domain":"sfatherapeutics.com","normalized_url_key":"sfatherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/5873834b208e59808a81e6f7b65403be4dd9fc78.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/sfa-therapeutics-inc","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://sfatherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://sfatherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","AI-powered Drug Discovery","Anti-Aging","Biotech","Health & Wellness","Biotechnology"],"stage":null,"founded_year":null,"location":"Philadelphia, PA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:58:19.617Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","AI-powered Drug Discovery","Anti-Aging","Biotech","Health & Wellness","Biotechnology"],"one_liner_for_search":"SFA Therapeutics — Regulating the immune system to block cancer & autoimmune diseases (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Active","Team size (per YC directory): 4","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: SFA Therapeutics, Inc.","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:58:19.617Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"anti-aging","name":"Anti-Aging","note":null,"profile_url":"/industries/anti-aging"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"health-and-wellness","name":"Health & Wellness","note":null,"profile_url":"/industries/health-and-wellness"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:58:19.617Z","updated_at":"2026-09-03T06:58:19.617Z"}},{"listing_type":"company","name":"Sensible Biotechnologies","slug":"sensible-biotechnologies","tagline":"Unlocking the next generation of mRNA medicines","description":"The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.\n\nSensible Biotechnologies is a Y Combinator company (Summer 2021). YC-listed status: Active.","url":"https://www.sensible.bio/","is_stealth":false,"normalized_domain":"sensible.bio","normalized_url_key":"sensible.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/45d14c57e3b4e2739c65c0bb84a511608548ffa2.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/sensible-biotechnologies","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.sensible.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.sensible.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Synthetic Biology","Biotech","Manufacturing","Biotechnology"],"stage":null,"founded_year":null,"location":"Oxford, England, United Kingdom","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:58:03.441Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","Synthetic Biology","Biotech","Manufacturing","Therapeutics","Biotechnology"],"one_liner_for_search":"Sensible Biotechnologies — Unlocking the next generation of mRNA medicines (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Active","Team size (per YC directory): 24","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Genbiotics","Regions (per YC): United Kingdom, Europe, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:58:03.441Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"biotechnology","name":"Biotechnology","note":null,"profile_url":"/industries/biotechnology"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"manufacturing","name":"Manufacturing","note":null,"profile_url":"/industries/manufacturing"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:58:03.441Z","updated_at":"2026-09-03T06:58:03.441Z"}},{"listing_type":"company","name":"Humane Genomics","slug":"humane-genomics","tagline":"A platform to make artificial viruses as cancer therapeutics.","description":"Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with \"2 factor authentication\" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.\n\nHumane Genomics is a Y Combinator company (Summer 2021). YC-listed status: Active.","url":"https://humanegenomics.com/","is_stealth":false,"normalized_domain":"humanegenomics.com","normalized_url_key":"humanegenomics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/47e90007a89a7dd904342a1da559cc31eb51d9a3.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/humane-genomics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://humanegenomics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://humanegenomics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Hard Tech","Synthetic Biology"],"stage":null,"founded_year":null,"location":"New York City, NY, USA; New York, NY, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:57:03.388Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","Hard Tech","Synthetic Biology"],"one_liner_for_search":"Humane Genomics — A platform to make artificial viruses as cancer therapeutics. (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:57:03.388Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"hard-tech","name":"Hard Tech","note":null,"profile_url":"/industries/hard-tech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:57:03.388Z","updated_at":"2026-09-03T06:57:03.388Z"}},{"listing_type":"company","name":"Inflow","slug":"inflow","tagline":"A self-help app for people to manage their ADHD.","description":"Inflow is a self-help app for people to manage their ADHD. They provide support through psychoeducation, habit development, and community.\n\nInflow is a Y Combinator company (Summer 2021). YC-listed status: Acquired.","url":"https://www.getinflow.io/","is_stealth":false,"normalized_domain":"getinflow.io","normalized_url_key":"getinflow.io","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/63a830ded6794d91b1e36abf5ae5bb0cb246fff3.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/inflow","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.getinflow.io/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.getinflow.io/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Mental Health Tech","Consumer Health Services"],"stage":null,"founded_year":null,"location":"London, England, United Kingdom; New York, NY, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:55:12.300Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","Mental Health Tech","Consumer Health Services"],"one_liner_for_search":"Inflow — A self-help app for people to manage their ADHD. (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Acquired","Team size (per YC directory): 20","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United Kingdom, United States of America, Europe, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:55:12.300Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"consumer-health-services","name":"Consumer Health Services","note":null,"profile_url":"/industries/consumer-health-services"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"mental-health-tech","name":"Mental Health Tech","note":null,"profile_url":"/industries/mental-health-tech"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:55:12.300Z","updated_at":"2026-09-03T06:55:12.300Z"}},{"listing_type":"company","name":"Yemaachi Biotechnology","slug":"yemaachi-biotechnology","tagline":"Diversifying precision cancer diagnostics and treatments","description":"Yemaachi Biotech is diversifying and expanding access to precision cancer diagnostics and therapeutics by collecting  and sequencing samples from all across Africa, which is the most genetically diverse population on the planet. We then use this data to either optimize existing diagnostic tests, or help other companies discover new ones.\nWith our research activities based in Africa, we are able to leverage access to the most genetically diverse population on the planet to build a first-of-its-kind clinical and molecular knowledgebase on cancer among African people.\n\nYemaachi Biotechnology is a Y Combinator company (Summer 2021). YC-listed status: Active.","url":"https://www.yemaachi.com/","is_stealth":false,"normalized_domain":"yemaachi.com","normalized_url_key":"yemaachi.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/0f20c99ceb3dc4f5663a9b43329248c249511272.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/yemaachi-biotechnology","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.yemaachi.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.yemaachi.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Diagnostics","Biotech","Therapeutics"],"stage":null,"founded_year":null,"location":"Accra, Greater Accra Region, Ghana","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:54:34.018Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","Biotech","Diagnostics","Therapeutics"],"one_liner_for_search":"Yemaachi Biotechnology — Diversifying precision cancer diagnostics and treatments (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Active","Team size (per YC directory): 16","YC industry: Healthcare","YC subindustry: Healthcare / Diagnostics","Regions (per YC): Ghana, Africa"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:54:34.018Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"diagnostics","name":"Diagnostics","note":null,"profile_url":"/industries/diagnostics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:54:34.018Z","updated_at":"2026-09-03T06:54:34.018Z"}},{"listing_type":"company","name":"SafeBeat","slug":"safebeat","tagline":"Guiding cardiac therapeutics - all from your phone","description":"Guiding cardiac therapeutics - all from your phone\n\nSafeBeat is a Y Combinator company (Summer 2021). YC-listed status: Active.","url":"https://safebeat.com/","is_stealth":false,"normalized_domain":"safebeat.com","normalized_url_key":"safebeat.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/acc0e68099b17b27bc8291119107847bd622a646.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/safebeat","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://safebeat.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://safebeat.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Medical Devices","AI-Enhanced Learning","Digital Health","Therapeutics"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:51:19.025Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","AI-Enhanced Learning","Medical Devices","Digital Health","Therapeutics"],"one_liner_for_search":"SafeBeat — Guiding cardiac therapeutics - all from your phone (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Active","Team size (per YC directory): 9","YC industry: Healthcare","YC subindustry: Healthcare / Medical Devices","Former names: SafeBeat Rx LLC, SafeBeat Rx","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:51:19.025Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-enhanced-learning","name":"AI-Enhanced Learning","note":null,"profile_url":"/industries/ai-enhanced-learning"},{"kind":"industry","slug":"digital-health","name":"Digital Health","note":null,"profile_url":"/industries/digital-health"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"medical-devices","name":"Medical Devices","note":null,"profile_url":"/industries/medical-devices"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:51:19.025Z","updated_at":"2026-09-03T06:51:19.025Z"}},{"listing_type":"company","name":"Catena Biosciences","slug":"catena-biosciences","tagline":"Using protein coupling to build new therapies","description":"Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.\n\nCatena Biosciences is a Y Combinator company (Summer 2021). YC-listed status: Active.","url":"https://catenabio.com/","is_stealth":false,"normalized_domain":"catenabio.com","normalized_url_key":"catenabio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/f1d289877a701c3b0826470c1e3ff501de0e4759.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/catena-biosciences","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://catenabio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://catenabio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; Berkeley, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:49:16.576Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","Biotech","Therapeutics"],"one_liner_for_search":"Catena Biosciences — Using protein coupling to build new therapies (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Active","Team size (per YC directory): 7","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:49:16.576Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:49:16.576Z","updated_at":"2026-09-03T06:49:16.576Z"}},{"listing_type":"company","name":"Promakhos Therapeutics","slug":"promakhos-therapeutics","tagline":"A therapeutics platform for curing inflammatory disorders","description":"We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.\n\nPromakhos Therapeutics is a Y Combinator company (Summer 2021). YC-listed status: Active.","url":"https://www.promakhos.com/","is_stealth":false,"normalized_domain":"promakhos.com","normalized_url_key":"promakhos.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/2bf583e0e272b341a471dca1a79bbef1feb19285.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/promakhos-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.promakhos.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.promakhos.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics"],"stage":null,"founded_year":null,"location":"Boston, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:48:04.686Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2021","Therapeutics"],"one_liner_for_search":"Promakhos Therapeutics — A therapeutics platform for curing inflammatory disorders (Y Combinator Summer 2021)","canonical_facts":["Y Combinator batch: Summer 2021","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Promakhos Therapeutics Inc.","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:48:04.686Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:48:04.686Z","updated_at":"2026-09-03T06:48:04.686Z"}},{"listing_type":"company","name":"Nuntius Therapeutics","slug":"nuntius-therapeutics","tagline":"Cell-specific genetic medicines","description":"Cell-specific genetic medicines\n\nNuntius Therapeutics is a Y Combinator company (Winter 2021). YC-listed status: Active.","url":"https://nuntiustx.com/","is_stealth":false,"normalized_domain":"nuntiustx.com","normalized_url_key":"nuntiustx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/490dca692522bd958768d197eafc08f9ea77c8fb.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/nuntius-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://nuntiustx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://nuntiustx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Gene Therapy","Nanomedicine"],"stage":null,"founded_year":null,"location":"London, England, United Kingdom","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:47:05.586Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2021","Gene Therapy","Nanomedicine"],"one_liner_for_search":"Nuntius Therapeutics — Cell-specific genetic medicines (Y Combinator Winter 2021)","canonical_facts":["Y Combinator batch: Winter 2021","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United Kingdom, Europe, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:47:05.586Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"nanomedicine","name":"Nanomedicine","note":null,"profile_url":"/industries/nanomedicine"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:47:05.586Z","updated_at":"2026-09-03T06:47:05.586Z"}},{"listing_type":"company","name":"Entelexo Biotherapeutics","slug":"entelexo-biotherapeutics","tagline":"Creating a New Class of Drugs to Address Incurable Autoimmune Diseases","description":"Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.\n\nEntelexo Biotherapeutics is a Y Combinator company (Winter 2021). YC-listed status: Active.","url":"https://www.entelexo.com/","is_stealth":false,"normalized_domain":"entelexo.com","normalized_url_key":"entelexo.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/2ef38251e4060b4827ae3ce45f0e73e1f6f1cb2d.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/entelexo-biotherapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.entelexo.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.entelexo.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech"],"stage":null,"founded_year":null,"location":"Irvine, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:44:29.984Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2021","Biotech"],"one_liner_for_search":"Entelexo Biotherapeutics — Creating a New Class of Drugs to Address Incurable Autoimmune Diseases (Y Combinator Winter 2021)","canonical_facts":["Y Combinator batch: Winter 2021","YC company status: Active","Team size (per YC directory): 3","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:44:29.984Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:44:29.984Z","updated_at":"2026-09-03T06:44:29.984Z"}},{"listing_type":"company","name":"Biodock","slug":"biodock","tagline":"Cloud AI microscopy automation","description":"Biodock's cloud platform accelerates microscopy analysis, automating months of microscopy analysis and infrastructure to minutes with our end-to-end AI architecture.  Scientists enjoy auto-scaling storage, GPU compute, and 30-50% more accurate analysis.\n\nWe're building an amazing experience to translate microscopy images to therapeutic insights for academic and enterprise scientists.\n\nBiodock is a Y Combinator company (Winter 2021). YC-listed status: Active.","url":"https://www.biodock.ai/","is_stealth":false,"normalized_domain":"biodock.ai","normalized_url_key":"biodock.ai","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ef18ff7a47b6ccba783538bb34567deafd6e5a0f.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/biodock","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.biodock.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.biodock.ai/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Deep Learning","SaaS","AI"],"stage":null,"founded_year":null,"location":"Austin, TX, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:44:16.832Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2021","Deep Learning","SaaS","AI"],"one_liner_for_search":"Biodock — Cloud AI microscopy automation (Y Combinator Winter 2021)","canonical_facts":["Y Combinator batch: Winter 2021","YC company status: Active","Team size (per YC directory): 8","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Biodock AI","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:44:16.832Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"deep-learning","name":"Deep Learning","note":null,"profile_url":"/industries/deep-learning"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"saas","name":"SaaS","note":null,"profile_url":"/industries/saas"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:44:16.832Z","updated_at":"2026-09-03T06:44:16.832Z"}},{"listing_type":"company","name":"Valink Therapeutics","slug":"valink-therapeutics","tagline":"Discovering bispecific antibody drug-conjugates (BsADC) against cancer","description":"Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.\n\nValink Therapeutics is a Y Combinator company (Winter 2021). YC-listed status: Active.","url":"https://www.valinktx.com/","is_stealth":false,"normalized_domain":"valinktx.com","normalized_url_key":"valinktx.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/4fdbac90b07fa4233736c11be944db20adb49e3b.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/valink-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.valinktx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.valinktx.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"Boston, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:40:15.298Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2021","Biotech","Therapeutics","Drug discovery"],"one_liner_for_search":"Valink Therapeutics — Discovering bispecific antibody drug-conjugates (BsADC) against cancer (Y Combinator Winter 2021)","canonical_facts":["Y Combinator batch: Winter 2021","YC company status: Active","Team size (per YC directory): 15","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: SpyCombinator, LiliumX","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:40:15.298Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:40:15.298Z","updated_at":"2026-09-03T06:40:15.298Z"}},{"listing_type":"company","name":"Serna Bio","slug":"serna-bio","tagline":"Genetic Medicine with Small Molecules","description":"Serna Bio is developing small molecules to modulate RNA function, unlocking the potential to treat diseases driven by biology intractable by other modalities.\n\nSerna Bio is a Y Combinator company (Winter 2021). YC-listed status: Active.","url":"https://www.serna.bio/","is_stealth":false,"normalized_domain":"serna.bio","normalized_url_key":"serna.bio","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/e5c345ecf4dc0bf6d96b3cb2f1e7485d78c1449d.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/serna-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.serna.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.serna.bio/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"Ontario, CA, USA; Remote","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:37:36.367Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2021","Biotech","Drug discovery"],"one_liner_for_search":"Serna Bio — Genetic Medicine with Small Molecules (Y Combinator Winter 2021)","canonical_facts":["Y Combinator batch: Winter 2021","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Ladder Therapeutics (LTX)","Regions (per YC): United States of America, America / Canada, Remote, Fully Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:37:36.367Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:37:36.367Z","updated_at":"2026-09-03T06:37:36.367Z"}},{"listing_type":"company","name":"Gilgamesh Pharmaceuticals","slug":"gilgamesh-pharmaceuticals","tagline":"Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…","description":"Gilgamesh is a pioneering, clinical stage mental health science-focused biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCEs) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.\n\nGilgamesh Pharmaceuticals is a Y Combinator company (Summer 2020). YC-listed status: Active.","url":"https://www.gilgameshpharmaceutical.com/","is_stealth":false,"normalized_domain":"gilgameshpharmaceutical.com","normalized_url_key":"gilgameshpharmaceutical.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/22862a35e633350fc6345c3ab3f594a54629f1b2.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/gilgamesh-pharmaceuticals","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.gilgameshpharmaceutical.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.gilgameshpharmaceutical.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Therapeutics","Psychedelics","Mental Health"],"stage":null,"founded_year":null,"location":"New York City, NY, USA; New York, NY, USA; Remote","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:37:24.257Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2020","Therapeutics","Psychedelics","Mental Health"],"one_liner_for_search":"Gilgamesh Pharmaceuticals — Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company… (Y Combinator Summer 2020)","canonical_facts":["Y Combinator batch: Summer 2020","YC company status: Active","Team size (per YC directory): 15","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Regions (per YC): United States of America, America / Canada, Remote, Fully Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:37:24.257Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"mental-health","name":"Mental Health","note":null,"profile_url":"/industries/mental-health"},{"kind":"industry","slug":"psychedelics","name":"Psychedelics","note":null,"profile_url":"/industries/psychedelics"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:37:24.257Z","updated_at":"2026-09-03T06:37:24.257Z"}},{"listing_type":"company","name":"Pardes Biosciences","slug":"pardes-bio","tagline":"We break viruses","description":"We make oral drugs to treat and prevent viral infections - like COVID-19.\n\nPardes Biosciences is a Y Combinator company (Summer 2020). YC-listed status: Public.","url":"https://www.pardesbio.com/","is_stealth":false,"normalized_domain":"pardesbio.com","normalized_url_key":"pardesbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/7a90b132bd3ef57761690e68c3355e7471e2abf7.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/pardes-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.pardesbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.pardesbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Biotech","Therapeutics"],"stage":"public","founded_year":null,"location":"San Francisco, CA, USA; Remote","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:36:18.989Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2020","Biotech","Therapeutics"],"one_liner_for_search":"Pardes Biosciences — We break viruses (Y Combinator Summer 2020)","canonical_facts":["Y Combinator batch: Summer 2020","YC company status: Public","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Pardes Biosciences","Listed in YC Top Companies","Regions (per YC): United States of America, America / Canada, Remote, Fully Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:36:18.989Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:36:18.989Z","updated_at":"2026-09-03T06:36:18.989Z"}},{"listing_type":"company","name":"Nephrogen","slug":"nephrogen","tagline":"Curative genetic medicines for kidney diseases","description":"Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. \n\nNephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.\n\nNephrogen is a Y Combinator company (Summer 2020). YC-listed status: Active.","url":"https://www.nephrogenbiotech.com/","is_stealth":false,"normalized_domain":"nephrogenbiotech.com","normalized_url_key":"nephrogenbiotech.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/ce4f8b04c9fefa06f0088d04f45b91af1e3fe8aa.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/nephrogen","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.nephrogenbiotech.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.nephrogenbiotech.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Gene Therapy","CRISPR","Biotech"],"stage":null,"founded_year":null,"location":"New York City, NY, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:35:29.787Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2020","Gene Therapy","CRISPR","Biotech"],"one_liner_for_search":"Nephrogen — Curative genetic medicines for kidney diseases (Y Combinator Summer 2020)","canonical_facts":["Y Combinator batch: Summer 2020","YC company status: Active","Team size (per YC directory): 5","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:35:29.787Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"crispr","name":"CRISPR","note":null,"profile_url":"/industries/crispr"},{"kind":"industry","slug":"gene-therapy","name":"Gene Therapy","note":null,"profile_url":"/industries/gene-therapy"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:35:29.787Z","updated_at":"2026-09-03T06:35:29.787Z"}},{"listing_type":"company","name":"Kernal Biologics","slug":"kernal-biologics","tagline":"Kernal is creating mRNA 2.0 therapies that work in specific cells","description":"Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week.\n \nKernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA.\n\nWith roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS).\n\nKernal Biologics is a Y Combinator company (Summer 2020). YC-listed status: Active.","url":"https://www.kernalbio.com/","is_stealth":false,"normalized_domain":"kernalbio.com","normalized_url_key":"kernalbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/1534fd5c3c1e4705596c793a4a59a28da388bacf.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/kernal-biologics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.kernalbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.kernalbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Artificial Intelligence","Biotech","Genomics"],"stage":null,"founded_year":null,"location":"Boston, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:34:16.014Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Summer 2020","Artificial Intelligence","Biotech","Genomics"],"one_liner_for_search":"Kernal Biologics — Kernal is creating mRNA 2.0 therapies that work in specific cells (Y Combinator Summer 2020)","canonical_facts":["Y Combinator batch: Summer 2020","YC company status: Active","Team size (per YC directory): 20","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:34:16.014Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"artificial-intelligence","name":"Artificial Intelligence","note":null,"profile_url":"/industries/artificial-intelligence"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"genomics","name":"Genomics","note":null,"profile_url":"/industries/genomics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:34:16.014Z","updated_at":"2026-09-03T06:34:16.014Z"}},{"listing_type":"company","name":"Algen Biotechnologies","slug":"algen-biotechnologies","tagline":"Using CRISPR to find treatments for cancer and inflammation","description":"Algen is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer, inflammation and diseases with high unmet needs. We are harnessing the power of CRISPR and machine learning to find first-in-class drugs that modulate RNA messages at single-cell resolution. Algen's founders are bioengineer from Jennifer Doudna Lab and biotech commercialization expert, teamed up with experienced pharmaceutical executives.\n\nAlgen Biotechnologies is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://www.algenbio.com/","is_stealth":false,"normalized_domain":"algenbio.com","normalized_url_key":"algenbio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/41218b0dee65a988940509b3fe258626c5137590.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/algen-biotechnologies","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.algenbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.algenbio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","CRISPR","Biotech","Therapeutics","Drug discovery","AI"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:32:33.310Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","CRISPR","Biotech","Therapeutics","Drug discovery","AI"],"one_liner_for_search":"Algen Biotechnologies — Using CRISPR to find treatments for cancer and inflammation (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 15","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Algen Biotechnologies, Inc.","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:32:33.310Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai","name":"AI","note":null,"profile_url":"/industries/ai"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"crispr","name":"CRISPR","note":null,"profile_url":"/industries/crispr"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:32:33.310Z","updated_at":"2026-09-03T06:32:33.310Z"}},{"listing_type":"company","name":"Ochre Bio","slug":"ochre-bio","tagline":"RNA medicines for liver diseases","description":"Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.\n\nOchre Bio is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://www.ochre-bio.com/","is_stealth":false,"normalized_domain":"ochre-bio.com","normalized_url_key":"ochre-bio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/d80993cda53fffe2cfd91762d630c27dc21561bf.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/ochre-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.ochre-bio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.ochre-bio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech","Genomics"],"stage":null,"founded_year":null,"location":"London, England, United Kingdom; Oxford, England, United Kingdom","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:32:30.493Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","Biotech","Genomics"],"one_liner_for_search":"Ochre Bio — RNA medicines for liver diseases (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 50","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United Kingdom, Europe, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:32:30.493Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"genomics","name":"Genomics","note":null,"profile_url":"/industries/genomics"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:32:30.493Z","updated_at":"2026-09-03T06:32:30.493Z"}},{"listing_type":"company","name":"Equator Therapeutics","slug":"equator-therapeutics","tagline":"We are developing a drug to burn calories and increase metabolism…","description":"We are developing a drug to increase metabolism and burn calories without exercise.\n\nObesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure.\n\nOur drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects.\n\nFor decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.\n\nEquator Therapeutics is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://equatortherapeutics.com/","is_stealth":false,"normalized_domain":"equatortherapeutics.com","normalized_url_key":"equatortherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/2c3115ee7654ff0be36a7d764f8dd7f98b178d2e.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/equator-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://equatortherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://equatortherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Biotech"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:32:25.771Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","Biotech","Therapeutics"],"one_liner_for_search":"Equator Therapeutics — We are developing a drug to burn calories and increase metabolism… (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 2","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:32:25.771Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:32:25.771Z","updated_at":"2026-09-03T06:32:25.771Z"}},{"listing_type":"company","name":"OpenBiome","slug":"openbiome","tagline":"A nonprofit stool bank enabling access to fecal transplants.","description":"We are a nonprofit stool bank, expanding safe access to fecal transplants and catalyzing research on the human microbiome.\n\nOpenBiome is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://openbiome.org/","is_stealth":false,"normalized_domain":"openbiome.org","normalized_url_key":"openbiome.org","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/25c85b99f2ca8aeb8dec9ea8945defebc1753fb2.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/openbiome","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://openbiome.org/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://openbiome.org/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","Nonprofit"],"stage":null,"founded_year":null,"location":"Boston, MA, USA; Cambridge, MA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:31:13.867Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","Nonprofit"],"one_liner_for_search":"OpenBiome — A nonprofit stool bank enabling access to fecal transplants. (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 70","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Nonprofit","Regions (per YC): United States of America, America / Canada, Remote, Partly Remote"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:31:13.867Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"nonprofit","name":"Nonprofit","note":null,"profile_url":"/industries/nonprofit"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:31:13.867Z","updated_at":"2026-09-03T06:31:13.867Z"}},{"listing_type":"company","name":"Altay Therapeutics","slug":"altay-therapeutics","tagline":"Altay develops disease-modifying therapies targeting transcription…","description":"Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer.  Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. \n\nWith a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. \n\nWe know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. \n\nWith our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.\n\nAltay Therapeutics is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://www.altaytherapeutics.com/","is_stealth":false,"normalized_domain":"altaytherapeutics.com","normalized_url_key":"altaytherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/altay-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.altaytherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.altaytherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","AI-powered Drug Discovery","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; South San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:29:27.996Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","AI-powered Drug Discovery","Biotech","Therapeutics","Drug discovery"],"one_liner_for_search":"Altay Therapeutics — Altay develops disease-modifying therapies targeting transcription… (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 6","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Altay Therapeutics Inc","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:29:27.996Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:29:27.996Z","updated_at":"2026-09-03T06:29:27.996Z"}},{"listing_type":"company","name":"Abalone Bio","slug":"abalone-bio","tagline":"We create activating antibodies to treat diseases others can’t.","description":"Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. \n\n+ High throughput experimental measurement uniquely leverages AI/ML:  We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of others. With our large, proprietary activity datasets, we uniquely leverage ML to both unlock the discovery of rare hits and generate optimized hits for challenging targets, starting with G-protein coupled receptors (GPCRs)\n\n+ Proven success: We have developed antibody agonists (activators) for 2 out of the 8 G-protein coupled receptors ever drugged by biotech.\n\n+ Pharma traction: We’ve secured 3 partnerships with $3M in revenue and $125M in downstream value. \n\n+ Externally validated science: We’ve been awarded $7M in non-dilutive grant funding for platform and program development.\n\nAbalone Bio is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://www.abalonebio.com/","is_stealth":false,"normalized_domain":"abalonebio.com","normalized_url_key":"abalonebio.com","parent_slug":null,"parent":null,"type_data":{},"logo":"https://bookface-images.s3.amazonaws.com/small_logos/e9f1d41bc9bfabd8ecaa9963112dc25b23472f0a.png","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/abalone-bio","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.abalonebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.abalonebio.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Drug Discovery and Delivery","Machine Learning","Synthetic Biology","Therapeutics","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:27:15.102Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","Machine Learning","Synthetic Biology","Therapeutics","Drug discovery"],"one_liner_for_search":"Abalone Bio — We create activating antibodies to treat diseases others can’t. (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 14","YC industry: Healthcare","YC subindustry: Healthcare / Drug Discovery and Delivery","Former names: Abalone Bio, Inc","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:27:15.102Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"drug-discovery-and-delivery","name":"Drug Discovery and Delivery","note":null,"profile_url":"/industries/drug-discovery-and-delivery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"machine-learning","name":"Machine Learning","note":null,"profile_url":"/industries/machine-learning"},{"kind":"industry","slug":"synthetic-biology","name":"Synthetic Biology","note":null,"profile_url":"/industries/synthetic-biology"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}],"membership":{"note":null,"source":"listing","added_via":"web","added_at":"2026-09-03T06:27:15.102Z","updated_at":"2026-09-03T06:27:15.102Z"}}],"total":72,"limit":50,"offset":0}